Pharmafile Logo
Pharmafocus logo
Advanced Search

AI-powered prognosis test company Spotlight Medical secures €6.2m in seed funding

July 15, 2024
Research and Development Oncology, Precision Medicine, Spotlight Medical, artificial intelligence, oncology, seed funding

Start-up Spotlight Medical has announced it has raised €6.2m in a seed funding round led by Kurma Partners and Heal Capital. …

News
heart-2372134_640

ApoC3 targeted by Sirnaomics through its announced completion of IND-Enabling studies of safety and efficacy for STP125G with NHP Models

July 15, 2024
Research and Development Cardiology, RNAi therapeutics, Sirnaomics, biopharmaceutical, cardiovascular, investigational new drug

Sirnaomics, a biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, has announced the completion of IND-enabling studies …

News
body scan

Pfizer selects once-daily obesity drug for advancement

July 12, 2024
Research and Development Obesity, Pfizer Inc, clinical trials, obesity

Pfizer has announced the selection of its preferred once-daily modified release formulation for danuglipron, with a plan to conduct dose …

News
lung_cancer_on_chest_x-ray

Imidex and Spesana collaborate over impact of AI in lung nodule and mass detection

July 12, 2024
Research and Development Imidex, Oncology, Spesana, artificial intelligence, cancer detection, lung cancer

Personalised medicine technology company Spesana and Imidex, developer of computer-aided detection technology, have announced a strategic partnership to research AI’s …

News

Aspect Biosystems announces partnership with governments of Canada and British Columbia

July 11, 2024
Business Services Aspect Biosciences, Pharmacy, government, investment

Aspect Biosystems has announced that it has entered into an agreement with the governments of Canada and British Columbia, under …

News

Biophytis gains IND approval from FDA for obesity study

July 11, 2024
Medical Communications Biophytis, IND, Obesity, clinical trial, obesity

Biophytis has announced that it has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) …

News

Pharmaxo acquired by Icon Group in strategic partnership

July 10, 2024
Business Services Oncology, Pharmaxo, acquisition, strategic parnership

Pharmaxo has announced that it is joining Icon Group as part of a strategic partnership intended to establish a global …

News

Certara to acquire Chemaxon for drug discovery portfolio

July 10, 2024
Business Services Certara, Chemaxon, Pharmacy, acquisition, drug discovery

Certara and Chemaxon have announced that they have signed a definitive agreement under which Certara will acquire Chemaxon. The deal …

News

iOnctura expands clinical trial programme for NSCLC

July 9, 2024
Research and Development NSCLC, Oncology, clinical trial, iOnctura, lung cancer

iOnctura has announced the expansion of its clinical trial programme for its lead pipeline asset, roginolisib.

News

Roche gains CE Mark for AI glucose monitoring system for diabetes management

July 9, 2024
Medical Communications AI, Diabetes, Roche, diabetes, glucose monitoring

Roche has announced that it has received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution.

News

Oxolife shares data from phase 2 trial for infertility drug

July 8, 2024
Research and Development Oxolife, Reproductive health, clinical trial, infertility

Oxolife has announced positive phase 2 clinical data on its fertility pill OXO-001 at the European Society of Human Reproduction …

News

AstraZeneca’s Tagrisso gains EU approval for lung cancer treatment

July 8, 2024
Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer

AstraZeneca has announced that the EU’s European Commission (EC) has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based …

News

GSK and CureVac to restructure collaboration into licensing agreement

July 3, 2024
Sales and Marketing CureVac, GSK, Immunology, License Agreement, collaboration

GSK and CureVac have announced that they have restructured their existing collaboration into a license agreement, which is intended to …

News

Eli Lilly’s Kisunla approved by FDA for Alzheimer’s treatment

July 3, 2024
Medical Communications Alzheimer's, Eli Lilly, Kisunla, Neurology

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for …

News

Arcturus Therapeutics provides update on OTC deficiency and CF programmes

July 2, 2024
Research and Development Arcturus Therapeutics, OTC, Pharmacy, clinical trials, cystic fibrosis

Arcturus Therapeutics has announced mid-year updates for ARCT-810, an investigational mRNA therapeutic to treat ornithine transcarbamylase (OTC) deficiency, and ARCT-032, …

News

NeuroSense shares update from ALS treatment trial

July 2, 2024
Research and Development NeuroSense, Neurology, als, clinical trial

NeuroSense has announced new statistically significant results from the 12-month analysis of its PARADIGM phase 2b study which assessed PrimeC …

News

Sanofi shares results from phase 2 trial for frexalimab in MS treatment

July 1, 2024
Research and Development MS, Neurology, Sanofi, multiple sclerosis

Sanofi has announced new phase 2 trial data for its CD40L monoclonal antibody, frexalimab, for the treatment of patients with …

News

EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention

July 1, 2024
Research and Development COVID-19, EMA, Infections and infestations, coronavirus

AstraZeneca has announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for sipavibart under the …

News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024
Business Services Alzheimers, Biogen, Eisai, Leqembi, Neurology, lecanemab

Eisai and Biogen have announced that Leqembi (lecanemab) has been launched in China as a treatment for mild cognitive impairment …

News

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024
Medical Communications AbbVie, CHMP, EMA, Oncology, follicular lymphoma

AbbVie has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026